Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases. - Nagle A; Biggart A; Be C; Srinivas H; Hein A; Caridha D; Sciotti RJ; Pybus B; Kreishman-Deitrick M; Bursulaya B; Lai YH; Gao MY; et al. (Journal of medicinal chemistry, 2020)